Stay updated on ANCHOR Clinical Trial: Melflufen+Dex+Bortez/Dara in RRMM

Sign up to get notified when there's something new on the ANCHOR Clinical Trial: Melflufen+Dex+Bortez/Dara in RRMM page.
Latest website image capture
Clouds background image

Latest updates to the ANCHOR Clinical Trial: Melflufen+Dex+Bortez/Dara in RRMM page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:34:04.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to an open-label Phase 1/2a study on the safety and efficacy of Melflufen and Dexamethasone in combination with either Bortezomib or Daratumumab for patients with relapsed or relapsed-refractory multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:48.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as age, prior diagnosis, and health conditions. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    51%
    Check dated 2024-05-22T20:30:31.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:34:49.000Z thumbnail image

Stay in the know with updates to ANCHOR Clinical Trial: Melflufen+Dex+Bortez/Dara in RRMM

Enter your email address, and we'll notify you when there's something new on the ANCHOR Clinical Trial: Melflufen+Dex+Bortez/Dara in RRMM page.